P2 receptors and platelet function
- 27 July 2011
- journal article
- Published by Springer Nature in Purinergic Signalling
- Vol. 7 (3) , 293-303
- https://doi.org/10.1007/s11302-011-9247-6
Abstract
Following vessel wall injury, platelets adhere to the exposed subendothelium, become activated and release mediators such as TXA2 and nucleotides stored at very high concentration in the so-called dense granules. Released nucleotides and other soluble agents act in a positive feedback mechanism to cause further platelet activation and amplify platelet responses induced by agents such as thrombin or collagen. Adenine nucleotides act on platelets through three distinct P2 receptors: two are G protein-coupled ADP receptors, namely the P2Y1 and P2Y12 receptor subtypes, while the P2X1 receptor ligand-gated cation channel is activated by ATP. The P2Y1 receptor initiates platelet aggregation but is not sufficient for a full platelet aggregation in response to ADP, while the P2Y12 receptor is responsible for completion of the aggregation to ADP. The latter receptor, the molecular target of the antithrombotic drugs clopidogrel, prasugrel and ticagrelor, is responsible for most of the potentiating effects of ADP when platelets are stimulated by agents such as thrombin, collagen or immune complexes. The P2X1 receptor is involved in platelet shape change and in activation by collagen under shear conditions. Each of these receptors is coupled to specific signal transduction pathways in response to ADP or ATP and is differentially involved in all the sequential events involved in platelet function and haemostasis. As such, they represent potential targets for antithrombotic drugs.Keywords
This publication has 160 references indexed in Scilit:
- Extracellular Ca2+ modulates ADP‐evoked aggregation through altered agonist degradation: implications for conditions used to study P2Y receptor activationBritish Journal of Haematology, 2011
- Quantification of recombinant and platelet P2Y1 receptors utilizing a [125I]-labeled high-affinity antagonist 2-iodo-N6-methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate ([125I]MRS2500)Pharmacological Research, 2010
- P2Y nucleotide receptors: promise of therapeutic applicationsDrug Discovery Today, 2010
- Platelets Amplify Inflammation in Arthritis via Collagen-Dependent Microparticle ProductionScience, 2010
- Platelets in defense against bacterial pathogensCellular and Molecular Life Sciences, 2009
- Leukotriene E4–induced pulmonary inflammation is mediated by the P2Y12 receptorThe Journal of Experimental Medicine, 2009
- Agonist-selective, Receptor-specific Interaction of Human P2Y Receptors with β-Arrestin-1 and -2Journal of Biological Chemistry, 2008
- Triggers, targets and treatments for thrombosisNature, 2008
- International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to TherapyPharmacological Reviews, 2006
- The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid raftsProceedings of the National Academy of Sciences, 2006